[{"orgOrder":0,"company":"SEARCHLIGHT PHARMA INC","sponsor":"Sol-Gel Technologies","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO\u00ae and EPSOLAY\u00ae in Canada","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"SEARCHLIGHT PHARMA INC","amount2":0.01,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"SEARCHLIGHT PHARMA INC \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"12","companyTruncated":"SEARCHLIGHT PHARMA INC \/ Searchlight Pharma Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA INC","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","amount":"$18.7 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra and Searchlight Pharma Announce Donesta\u00ae Licensing Agreement for Canada","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"July 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"SEARCHLIGHT PHARMA INC","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"SEARCHLIGHT PHARMA INC \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"10","companyTruncated":"SEARCHLIGHT PHARMA INC \/ Searchlight Pharma Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA INC","sponsor":"Mithra Pharmaceuticals","pharmaFlowCategory":"D","amount":"$17.9 million","upfrontCash":"Undisclosed","newsHeadline":"Mithra and Searchlight Pharma Sign DONESTA\u00ae Licensing Agreement for Canada","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatus":"Phase III","country":"","productType":"Small molecule","productStatus":"Approved","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Estetrol","moa":"","url1":"","url2":"","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"SEARCHLIGHT PHARMA INC","amount2":0.02,"therapeuticAreaNew":"Obstetrics\/Gynecology (Women\u2019s Health)","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","productSubType":"Hormone","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"SEARCHLIGHT PHARMA INC \/ Searchlight Pharma Inc","highestDevelopmentStatusID":"10","companyTruncated":"SEARCHLIGHT PHARMA INC \/ Searchlight Pharma Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA INC","sponsor":"Apotex Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apotex to Acquire Searchlight Pharma, a Canadian Specialty Branded Pharmaceutical Leader","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2024","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"SEARCHLIGHT PHARMA INC","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"Cream","sponsorNew":"SEARCHLIGHT PHARMA INC \/ Apotex Inc","highestDevelopmentStatusID":"12","companyTruncated":"SEARCHLIGHT PHARMA INC \/ Apotex Inc"},{"orgOrder":0,"company":"SEARCHLIGHT PHARMA INC","sponsor":"Apotex Inc","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apotex Acquires Searchlight, a Canadian Specialty Innovative Branded Pharma Company","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"June 2024","year":"2024","type":"Acquisition","leadProduct":"Tretinoin","moa":"","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved","graph3":"SEARCHLIGHT PHARMA INC","amount2":0,"therapeuticAreaNew":"Dermatology","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","productSubType":"Vitamins\/Minerals\/Inorganic Salts","amount2New":0,"dosageForm":"","sponsorNew":"SEARCHLIGHT PHARMA INC \/ Apotex Inc","highestDevelopmentStatusID":"12","companyTruncated":"SEARCHLIGHT PHARMA INC \/ Apotex Inc"}]

Find Clinical Drug Pipeline Developments & Deals by SEARCHLIGHT PHARMA INC

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris.

                          Brand Name : Twyneo

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 03, 2024

                          Lead Product(s) : Tretinoin,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Apotex Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          02

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : Through the acquisition, Apotex will commercialize Twyneo (tretinoin), a retinoic acid receptor agonist in combination with Benzoyl Peroxide indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older.

                          Brand Name : Twyneo

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          April 02, 2024

                          Lead Product(s) : Tretinoin,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Sponsor : Apotex Inc

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          03

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : Under the terms of the agreement, Searchlight will have sales and marketing rights for DONESTA® in Canada. DONESTA (estetrol) phase 3 clinical program, which demonstrated a meaningful reduction in the frequency and severity of vasomotor symptoms compare...

                          Brand Name : Donesta

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 26, 2023

                          Lead Product(s) : Estetrol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Recipient : Mithra Pharmaceuticals

                          Deal Size : $17.9 million

                          Deal Type : Licensing Agreement

                          blank

                          04

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : Under the agreement, Searchlight will have the Canadian rights to Donesta, a next generation orally administered Estetrol (E4)-based hormone therapy product, for the treatment of the symptoms of menopause.

                          Brand Name : Donesta

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 31, 2023

                          Lead Product(s) : Estetrol

                          Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                          Highest Development Status : Phase III

                          Recipient : Mithra Pharmaceuticals

                          Deal Size : $18.7 million

                          Deal Type : Licensing Agreement

                          blank

                          05

                          Discovery on Target
                          Not Confirmed
                          Discovery on Target
                          Not Confirmed

                          Details : Under the agreement, Searchlight Pharma will be responsible for obtaining and maintaining any regulatory approvals required to market and sell Twyneo (tretinoin), used for acne vulgaris and Epsolay (benzoyl peroxide), used for inflammatory lesions of ros...

                          Brand Name : Twyneo

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          June 06, 2023

                          Lead Product(s) : Tretinoin,Benzoyl Peroxide

                          Therapeutic Area : Dermatology

                          Highest Development Status : Approved

                          Recipient : Sol-Gel Technologies

                          Deal Size : $11.0 million

                          Deal Type : Licensing Agreement

                          blank